Label-free target identification reveals oxidative DNA damage as the mechanism of a selective cytotoxic agent† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8sc05465g

Target proteins and mechanism of a HeLa-specific cytotoxic compound were investigated by two thermal shift-based label-free proteomics methods.

• Publication year

  2019

• Venue

  Chemical Science

• Publication date

  2019-02-19

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1039/c8sc05465gPMID 30996934PMCID 6438152
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How many human proteoforms are there?

  2018cited by this paper
• Opportunities and challenges in phenotypic drug discovery: an industry perspective

  2017cited by this paper
• Natural product inspired compound collections: evolutionary principle, chemical synthesis, phenotypic screening, and target identification.

  2017cited by this paper
• Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality

  2017cited by this paper
• Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors

  2017cited by this paper
• The resurgence of phenotypic screening in drug discovery and development

  2016cited by this paper
• Label-free target identification using in-gel fluorescence difference via thermal stability shift

  2016cited by this paper
• Validation and development of MTH1 inhibitors for treatment of cancer.

  2016cited by this paper
• Thermal profiling reveals phenylalanine hydroxylase as an off-target of panobinostat.

  2016cited by this paper
• Identification of cancer cytotoxic modulators of PDE3A by predictive chemogenomics

  2015cited by this paper
• Leukotriene C4 is the major trigger of stress-induced oxidative DNA damage

  2015cited by this paper
• Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling

  2015cited by this paper
• Thermal proteome profiling monitors ligand interactions with cellular membrane proteins

  2015cited by this paper
• Back to the future with phenotypic screening.

  2014cited by this paper
• Proteogenomic analysis reveals unanticipated adaptations of colorectal tumor cells to deficiencies in DNA mismatch repair.

  2014cited by this paper
• MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool

  2014cited by this paper
• DNA Mismatch Repair and Oxidative DNA Damage: Implications for Cancer Biology and Treatment

  2014cited by this paper
• Privileged structures: efficient chemical "navigators" toward unexplored biologically relevant chemical spaces.

  2014cited by this paper
• Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy

  2014cited by this paper
• Tracking cancer drugs in living cells by thermal profiling of the proteome

  2014cited by this paper
• The revolution and evolution of shotgun proteomics for large-scale proteome analysis.

  2013cited by this paper
• Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

  2013cited by this paper
• Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress

  2013cited by this paper
• Target identification and mechanism of action in chemical biology and drug discovery.

  2013cited by this paper
• Target identification for small bioactive molecules: finding the needle in the haystack.

  2013cited by this paper
• DNA damage sensing by the ATM and ATR kinases.

  2013cited by this paper
• Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers.

  2011cited by this paper
• How were new medicines discovered?

  2011cited by this paper
• Identification of a Primary Target of Thalidomide Teratogenicity

  2010cited by this paper
• A Critical Role for LTA4H in Limiting Chronic Pulmonary Neutrophilic Inflammation

  2010cited by this paper
• An efficient one-step synthesis of heterobiaryl pyrazolo[3,4-b]pyridines via indole ring opening.

  2009cited by this paper
• Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2

  2009cited by this paper
• Mechanisms and functions of DNA mismatch repair

  2008cited by this paper
• The comet assay: a method to measure DNA damage in individual cells

  2006cited by this paper
• Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells.

  2005cited by this paper
• The Concept of Synthetic Lethality in the Context of Anticancer Therapy

  2005cited by this paper
• The Oxidized Deoxynucleoside Triphosphate Pool Is a Significant Contributor to Genetic Instability in Mismatch Repair-Deficient Cells

  2004cited by this paper
• The mammalian mismatch repair pathway removes DNA 8-oxodGMP incorporated from the oxidized dNTP pool.

  2002cited by this paper
• Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase I: in vitro studies.

  2002cited by this paper
• The Oxidized Forms of dATP Are Substrates for the Human MutT Homologue, the hMTH1 Protein*

  1999cited by this paper
• Direct detection of 8-oxodeoxyguanosine and 8-oxoguanine by avidin and its analogues.

  1998cited by this paper
• Cloning and expression of cDNA for a human enzyme that hydrolyzes 8-oxo-dGTP, a mutagenic substrate for DNA synthesis.

  1993cited by this paper
• MutT protein specifically hydrolyses a potent mutagenic substrate for DNA synthesis

  1992cited by this paper
• 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G----T and A----C substitutions.

  1992cited by this paper
• Leukotriene A4 hydrolase in the human B-lymphocytic cell line Raji: indications of catalytically divergent forms of the enzyme.

  1991cited by this paper
• Leukotriene A4 hydrolase from guinea pig lung: the presence of two catalytically active forms.

  1989cited by this paper

• Discovery of Novel Aromatic Urea-Imidazole Salt Derivatives for Cancer Therapy via Targeting ERK1/2.

  2025cites this paper
• Drug target proteome profiling identifies HES1-driven mitotic catastrophe in ovarian serous carcinoma.

  2025cites this paper
• Proteome profiling reveals HES1-driven mitotic catastrophe in ovarian serous carcinoma

  2025cites this paper
• Metabolite Functions Revealed by Mass Spectrometry-Based Target Engagement Proteomics Approaches.

  2025cites this paper
• Redox regulation: mechanisms, biology and therapeutic targets in diseases

  2025cites this paper
• MTH1 in the disorders of the central nervous system: scope beyond brain tumors and challenges

  2025cites this paper
• Targeting the nucleic acid oxidative damage repair enzyme MTH1: a promising therapeutic option

  2024cites this paper
• Inflachromene ameliorates Parkinson's disease by targeting Nrf2-binding Keap1

  2024cites this paper
• CETSA and thermal proteome profiling strategies for target identification and drug discovery of natural products.

  2023cites this paper
• An update of label-free protein target identification methods for natural active products

  2022cites this paper
• The Role of Protein Arginine Methyltransferases in DNA Damage Response

  2022cites this paper
• Activatable Self-Dissociation of Watson-Crick Structures with Fluorescent Nucleotides for Sensing Multiple Human Glycosylases at Single-Cell Level.

  2022cites this paper
• Recent advances in proteome‐wide label‐free target deconvolution for bioactive small molecules

  2021cites this paper
• Callyspongiolide kills cells by inducing mitochondrial dysfunction via cellular iron depletion

  2021cites this paper
• Chemoproteomic-enabled phenotypic screening.

  2021cites this paper
• Phenotypic Discovery of SB1501, an Anti‐obesity Agent, through Modulating Mitochondrial Activity

  2021cites this paper
• Targeting human MutT homolog 1 (MTH1) for cancer eradication: current progress and perspectives

  2020influential citation
• Recent advances in identifying protein targets in drug discovery.

  2020cites this paper
• AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma

  2020cites this paper
• Domino Transformations of Ene/yne Tethered Salicylaldehyde Derivatives: Pluripotent Platforms for the Construction of High Sp3 Content and Privileged Architectures.

  2019cites this paper
• Construction of a self-directed replication system for label-free and real-time sensing of repair glycosylases with zero background† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc04738g

  2019cites this paper
• Karonudib is a promising anticancer therapy in hepatocellular carcinoma

  2019cites this paper
• Phenotype-based discovery of a HeLa-specific cytotoxic molecule that downregulates HPV-mediated signaling pathways via oxidative damage.

  2019cites this paper
• Label-free target identification in drug discovery via phenotypic screening.

  2019cites this paper